Our Products
Our global product portfolio enables clinicians to be more efficient and effective in treating patients at the hospital bedside, in the operating theater, in critical care units, at home and in the dialysis clinic. We are working alongside our partners to find new and smarter ways to improve patient outcomes, prevent complications before they become life-threatening and increase access to care, while reducing total costs.
The information contained on this page is intended for healthcare professionals only.
Product eCatalog
See our e-catalog which includes prescribing and ordering information
Product Security
Read about Baxter’s commitment to product security, our approach and important product security bulletins
Featured Global Products
CAELYX
Behandlung von Patientinnen mit metastasierendem Mammakarzinom, wenn eine Monotherapie mit Anthrazyklinen geeignet ist.
HOMECHOICE CLARIA with SHARESOURCE for Renal Care
HOMECHOICE CLARIA Automated peritoneal dialysis (APD) system with the SHARESOURCE remote patient management platform has user-friendly features that help end-stage renal disease patients manage their home peritoneal dialysis (PD) therapy, while keeping them remotely connected with their healthcare providers.
The HOMECHOICE CLARIA APD system with the SHARESOURCE remote patient management platform is approved in select European, Asian, and Latin American countries.
FLOSEAL Hemostatic Matrix for Surgical Care
FLOSEAL is an adjunct hemostatic agent proven effective in a wide-range of bleeding scenarios3 with a proprietary combination of two independent hemostatic agents.4,5
FLOSEAL Hemostatic Matrix is available in select countries globally.
HDx Enabled by THERANOVA for Renal Care
HDx enabled by THERANOVA is a new dialysis therapy we are pioneering for patients with end-stage renal disease. The THERANOVA dialyzer features an innovative membrane, which provides an expanded hemodialysis therapy (HDx).
HDx enabled by THERANOVA is available in Canada and select European, Latin American and Asian markets.
PRISMAFLEX System for Critical Care
The innovative PRISMAFLEX System is designed to support the recovery of critically ill patients with acute kidney injury (AKI). The flexible system meets the demands of multiple therapies with a versatile platform that can be customized to specific patient needs.
PRISMAFLEX System is available in select countries globally.
New Product Overview
New Product Overview for Peritoneal Dialysis – Hemodialysis – Acute Therapies
In January 2023, the Baxter Group announced its plan to split into two independent healthcare companies globally.
Baxter remains a leading global medical device and pharmaceutical company focused on offering advanced technologies to hospitals and ambulatory care services, including infusion systems, smart beds, parenteral nutrition, surgical devices, injectable drugs, diagnostic devices, and connected care solutions.
Vantive, which will emerge from Baxter's current Renal Care and Acute Therapies businesses, will be a leader in kidney disease and other vital organ support therapies. The new independent company will build on nearly 70 years of pioneering work, offering a range of innovative technologies, digital connectivity and services designed to meet the needs of physicians and patients in more than 70 countries worldwide.
As a result of the imminent division of the company in Austria, you will experience some administrative or operational changes, which we describe below.
As a current customer of our company and our products, which will be split between the two companies, you will be a future customer of Baxter and Vantive. Our new Vantive company in Austria, Vantive Health Austria GmbH, is expected to start its full distribution operations on May 1, 2024. Therefore, you should create Vantive Health Austria GmbH as a new supplier in your system by this time.
All products that you currently order from Baxter for the care of your peritoneal and hemodialysis patients as well as acute therapies will be available to order from Vantive in the future. All other current Baxter products will remain with Baxter, but the process for ordering and contacting them will remain unchanged.
In order to prepare for this change, please make the following administrative changes for the facility of "Vantive Health Austria GmbH" before May 1, 2024:
- Company Name : Vantive Health Austria GmbH
- Address of the company : Stella-Klein-Löw-Weg 15, 1020 Wien
- Commercial register number : FN 607524 v
- Steuernummer : 06 104/9060
- ATU Nummer : ATU79775414
- Bank account : DEUTSCHE BANK, BIC DEUTATWWXXX IBAN AT25 1910 0000 3332 0001
- Telephone : + 43 1 71120 - 0
Under the following link you will find the product codes that can be ordered from Vantive Health Austria GmbH from May 1, 2024:
Product overview >
